Cure My Disease

Don't miss your cure!

 Log in / Sign up

New biologic drug aims to clear stubborn eczema in just 24 weeks

NCT ID NCT05990725

Completed Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether lebrikizumab, an injectable biologic, can improve skin symptoms in adults and adolescents (aged 12 and older) with moderate-to-severe atopic dermatitis, also known as eczema. Participants receive lebrikizumab for 24 weeks, and doctors measure changes in eczema severity using a standard skin score. The goal is to see if this treatment can reduce redness, thickening, and itching enough to make a real difference in daily life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lebrikizumab, an injectable biologic drug
What this could lead to
If successful, lebrikizumab could offer a new treatment option for people with moderate-to-severe eczema, helping to clear skin and reduce itching.
What could go wrong
This is an open-label study without a placebo group, so results may be less reliable. Side effects from lebrikizumab are possible, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ECZEMA

Contacts and locations

Locations

  • Site 1

    Kiel, Germany

  • Site 10

    Lübeck, Germany

  • Site 11

    Erlangen, Germany

  • Site 12

    Oberhausen, Germany

  • Site 13

    München, Germany

  • Site 14

    York, United Kingdom

  • Site 15

    Hamburg, Germany

  • Site 17

    München, Germany

  • Site 18

    Tübingen, Germany

  • Site 19

    Langenau, Germany

  • Site 2

    Potsdam, Germany

  • Site 22

    Oldenburg, Germany

  • Site 23

    Heidelberg, Germany

  • Site 26

    Mainz, Germany

  • Site 27

    Dresden, Germany

  • Site 28

    Düsseldorf, Germany

  • Site 29

    Bonn, Germany

  • Site 3

    Hamburg, Germany

  • Site 30

    Regensburg, Germany

  • Site 32

    Freiburg im Breisgau, Germany

  • Site 33

    München, Germany

  • Site 34

    Augsburg, Germany

  • Site 35

    Bergen op Zoom, Netherlands

  • Site 36

    Marburg, Germany

  • Site 37

    Frankfurt, Germany

  • Site 38

    Leeds, United Kingdom

  • Site 4

    Münster, Germany

  • Site 41

    Utrecht, Netherlands

  • Site 5

    Göttingen, Germany

  • Site 6

    Mannheim, Germany

  • Site 7

    Rostock, Germany

  • Site 8

    Hamburg, Germany

  • Site 9

    Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.